Recorded Webinar: Collaboration Opportunities with Daiichi Sankyo in Early Stage Research and Technology

Daiichi Sankyo

Daiichi Sankyo, the global pharmaceutical company with corporate origins in Japan is seeking research collaborations with UK entities in a number of key areas. The Department for International Trade worked with Daiichi Sankyo and One Nucleus to organise a free webinar to enable you to learn about the Daiichi Sankyo research priorities and collaboration structures available. The core areas of interest include:
  • Novel modality technologies in oncology and CNS (psychiatric and neurodegenerative disease)
  • Ex) Target protein degrader (except E3 binder), conditional active antibody (except pH-dependent), next generation of gene therapy etc
  • Novel drug delivery technologies to cancer cells or brain after systemic administration
  • Ex) Engineered nanoparticle/exosome etc Novel target or cancer-specific antigen for antibody in oncology
This content has been restricted to logged in users only. Please login to view this content.

The remainder of this article is a resource for members only. Please register or login to access. 

Get free and unlimited access to in-depth market reports, videos, invitations to relevant events and priority support. Join here.